Drugs / OSAVAMPATOR
OSAVAMPATOR
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03792672 | Feb → May 2019 | — | Neurocrine Biosciences | Completed | No outcome recorded |
| Phase 1 | NCT02561156 | Aug 2015 → Sep 2017 | depressive disorder | Neurocrine Biosciences | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05203341 | Feb 2022 → Jan 2024 | major depressive disorder | Neurocrine Biosciences | Completed | No outcome recorded |
| Phase 2 | NCT03312894 | Feb 2018 → Feb 2019 | — | Millennium Pharmaceuticals, Inc. | Withdrawn | No outcome recorded |
| Phase 35 trials | ||||||
| Phase 3 | NCT07196501 | Aug 2025 → Jul 2028 expected | major depressive disorder | Neurocrine Biosciences | Recruiting | No outcome recorded |
| Phase 3 | NCT06963021 | May 2025 → Jul 2027 expected | major depressive disorder | Neurocrine Biosciences | Recruiting | No outcome recorded |
| Phase 3 | NCT06966401 | Apr 2025 → May 2029 expected | major depressive disorder | Neurocrine Biosciences | Recruiting | No outcome recorded |
| Phase 3 | NCT06911112 | Mar 2025 → Jul 2027 expected | major depressive disorder | Neurocrine Biosciences | Recruiting | No outcome recorded |
| Phase 3 | NCT06786624 | Jan 2025 → Jul 2027 expected | major depressive disorder | Neurocrine Biosciences | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OSAVAMPATOR | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594403 ↗ |
| Known as | NBI-1065845 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05203341 ↗ |
| Known as | TAK-653 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03312894 ↗ |
| Modality | Small molecule | — CHEMBL4594403 ↗ |
| Route | Oral | “TAK-653 0.3 mg, tablet, orally, once on Day 1” NCT02561156 ↗ |